2020

Genes

Rocznik: 2020 | Tom: 11 | Numer: 7

artykuł naukowy

angielski

EN Over the last two decades, numerous BARD1 mutations/pathogenic variants (PVs) have been found in patients with breast cancer (BC) and ovarian cancer (OC). However, their role in BC and OC susceptibility remains controversial, and strong evidence-based guidelines for carriers are not yet available. Herein, we present a comprehensive catalog of BARD1PVs identified in large cumulative cohorts of similar to 48,700 BC and similar to 20,800 OC cases (retrieved from 123 studies examining the whole coding sequence ofBARD1). Using these resources, we compared the frequency of BARD1 PVs in the cases and similar to 134,100 controls from the gnomAD database and estimated the effect of the BARD1 PVs on BC and OC risks. The analysis revealed that BARD1 is a BC moderate-risk gene (odds ratio (OR) = 2.90, 95% CIs:2.25-3.75, p< 0.0001) but not an OC risk gene (OR = 1.36, 95% CIs:0.87-2.11,p=0.1733). In addition, the BARD1 mutational spectrum outlined in this study allowed us to determine recurrent PVs and evaluate the variant-specific risk for the most frequent PVs. In conclusion, these precise estimates improve the understanding of the role of BARD1 PVs in BC and OC predisposition and support the need for BARD1 diagnostic testing in BC patients.

798

10.3390/genes11070798

https://www.mdpi.com/2073-4425/11/7/798/pdf

CC BY-NC-SA (uznanie autorstwa - użycie niekomercyjne - na tych samych warunkach)

ostateczna wersja opublikowana

02.2020

w momencie opublikowania

100

100